妊娠期意外暴露于新型口服2型脊髓灰质炎疫苗的安全性:莫桑比克2022-2023年纵向观察性研究
在莫桑比克楠普拉(暴露队列)和马普托(非暴露队列)开展观察性研究,2022年8月至2023年6月纳入326名和940名孕妇。暴露队列死产、低出生体重、先天畸形、新生儿死亡和孕产妇死亡与非暴露队列无显著差异,但早产率升高(18.4% vs 11.0%,p=0.011)。结论认为未观察到被动暴露nOPV2导致不良妊娠结局增加,早产率升高需进一步调查,数据支持继续使用nOPV2应对脊灰疫情及疫苗全面许可。
要点
- 暴露队列与非暴露队列的死产、低出生体重、先天畸形、新生儿和孕产妇死亡均无显著差异。
- 暴露队列早产率高于非暴露队列(18.4% vs 11.0%,p=0.011),需进一步调查。
- 数据支持继续使用nOPV2应对脊灰疫情及疫苗全面许可。
核心结论
- 未观察到因被动暴露nOPV2导致不良妊娠结局频率增加。
- 暴露队列早产率升高需进一步调查。
- 数据支持继续使用nOPV2应对脊灰疫情及疫苗全面许可。
研究设计与样本
- 在莫桑比克楠普拉(暴露队列)和马普托(非暴露队列)开展的观察性研究,2022年8月至2023年6月进行。
- 楠普拉开展两轮nOPV2接种活动,马普托未开展。
- 从楠普拉纳入326名孕妇,从马普托市纳入940名孕妇。
- 在常规产前检查、分娩和新生儿28天访视时随访产科异常和妊娠结局,并采集社会人口学、病史和产科史。
主要发现
- 死产率暴露队列2.3% vs 非暴露队列1.6%(p=0.438)。
- 低出生体重率暴露队列8.9% vs 非暴露队列8.2%(p=0.989)。
- 先天畸形率暴露队列1% vs 非暴露队列0.5%(p=0.454)。
- 新生儿死亡率暴露队列2.3% vs 非暴露队列1.6%(p=0.08)。
- 孕产妇死亡率暴露队列0% vs 非暴露队列0.2%(p=0.978)。
局限性
- 早产率升高需进一步调查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To minimize the risk of vaccine-derived poliovirus emergences, the novel oral poliovirus vaccine type 2 (nOPV2), was bioengineered to have increased genetic stability compared to Sabin OPV and recommended for outbreak response Emergency Use Listing by WHO. Although pregnant women are not a target population for this vaccine, a theoretical risk of incidental exposure exists via pharyngeal or faecal shedding from vaccinated children in the household or close community. METHODS: This was an observational study of pregnant women conducted in Nampula (exposed cohort) and Maputo (non-exposed cohort) in Mozambique from August 2022 to June 2023. Two nOPV2 campaigns were conducted in Nampula and none in Maputo. Women were followed-up during routine prenatal consultation, delivery, and 28-day neonate visits for obstetric anomalies and pregnancy outcomes. Sociodemographic, medical, and obstetric history was captured. RESULTS: Three hundred twenty-six pregnant women were enrolled from Nampula and 940 from Maputo City. Stillbirth prevalence (2·3% vs 1·6%, p = 0·438), low birth weight (8·9% vs 8·2%, p = 0·989), congenital anomalies (1 % vs 0·5%, p = 0·454), neonatal death (2·3% vs 1·6%, p = 0·08), and maternal death (0 % vs 0·2%, p = 0·978) did not differ amongst exposed and non-exposed cohorts. There was an increased rate of pre-term delivery in the exposed cohort (18·4% vs 11·0%, p = 0·011). CONCLUSION: We did not observe an increased frequency of adverse pregnancy outcomes due to passive nOPV2 exposure. A higher frequency of preterm delivery needs to be further investigated. The data reported herein support the continued use of nOPV2 for poliovirus outbreak response and full licensure of the vaccine.
引用
- de Deus N, Chissaque A, Bauhofer A, et al. Safety of incidental exposure to the novel oral poliovirus vaccine type 2 in pregnancy: A longitudinal observational study in Mozambique, 2022-2023. Vaccine. 2024. PMID: 38307745. doi:10.1016/j.vaccine.2024.01.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。